Trial Profile
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Oct 2009
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 31 Oct 2009 New trial record.